TY - JOUR
T1 - Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers
AU - Mauzo, Shakuntala H.
AU - Milton, Denái R.
AU - Prieto, Victor G.
AU - Torres-Cabala, Carlos A.
AU - Wang, Wei Lien
AU - Chakravarti, Nitin
AU - Nagarajan, Priyadharsini
AU - Tetzlaff, Michael T.
AU - Curry, Jonathan L.
AU - Ivan, Doina
AU - Brown, Robert E.
AU - Aung, Phyu P.
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/6
Y1 - 2018/6
N2 - Background: Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity. Design: Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody. Results: SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients. Conclusion: We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.
AB - Background: Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity. Design: Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody. Results: SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients. Conclusion: We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.
KW - AFX
KW - Cutaneous angiosarcoma
KW - Immunohistochemical study
KW - Kaposi Sarcoma
KW - Melanoma
KW - SPARC expression
UR - http://www.scopus.com/inward/record.url?scp=85045281450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045281450&partnerID=8YFLogxK
U2 - 10.1016/j.anndiagpath.2018.03.005
DO - 10.1016/j.anndiagpath.2018.03.005
M3 - Article
C2 - 29660567
AN - SCOPUS:85045281450
SN - 1092-9134
VL - 34
SP - 151
EP - 154
JO - Annals of Diagnostic Pathology
JF - Annals of Diagnostic Pathology
ER -